Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors
Shots:
- The US FDA has cleared the IND application of the company’s HBM9027 to commence FIH study across the US based on its anti-tumor activity and favorable safety profile due to its crosslinking dependent specificity on tumors and immune modulation activity in pre-clinical studies
- The P-I trial is designed to investigate HBM9027’s safety, tolerability, PK and anti-tumor activity in patients with advanced solid tumors
- HBM9027, based on HBICE platform, is a PD-L1xCD40 bispecific Ab that activates CD40 relied on PD-L1 crosslinking in multiple solid tumors
Ref: Harbour BioMed | Image: Harbour BioMed
Related Post:- Immunovant Reports Results of Batoclimab in P-II Trial for the Treatment of Graves’ Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
